(19 days)
Not Found
No
The document describes a wound dressing made of honey and alginate, with no mention of AI or ML technology.
Yes
The device is indicated for various wound types, including diabetic foot ulcers and burns, and helps in wound healing by providing a moist environment. These are therapeutic applications.
No
The device is a wound dressing designed to provide a moist environment for healing, not to diagnose a condition.
No
The device description clearly indicates it is a physical wound dressing comprised of honey and sodium alginate, not software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states that the device is a wound dressing for managing various types of wounds. This is a therapeutic application, not a diagnostic one.
- Device Description: The description details the composition and function of a wound dressing (honey and alginate for moist wound management and debridement). This aligns with a medical device used for treatment, not for analyzing samples from the body to diagnose a condition.
- Lack of Diagnostic Elements: There is no mention of analyzing biological samples (blood, urine, tissue, etc.), detecting biomarkers, or providing information for diagnosis.
IVD devices are used in vitro (outside the body) to examine specimens derived from the human body to provide information for the diagnosis, monitoring, or treatment of a disease or condition. This device is applied in vivo (on the body) for wound care.
N/A
Intended Use / Indications for Use
The Derma Sciences Honey Primary Wound Dressing provides a moist environment conducive to wound healing and is indicated for light to moderately wounds such as:
- . diabetic foot ulcers
- . leg ulcers (venous stasis ulcers, arterial ulcers and leg ulcers of mixed etiology)
- . pressure ulcers / sores (partial and full thickness)
- 1st and 2nd degree partial thickness burns
- ♥ donor sites, and traumatic and surgical wounds.
The Derma Sciences Medihoney Primary Dressing with Active Manuka Honey provides a moist environment conducive to wound healing and is indicated for light to moderately exuding wounds such as:
- . diabetic foot ulcers
- leg ulcers (venous stasis ulcers, arterial ulcers and leg ulcers of mixed . etiology)
- pressure ulcers / sores (partial and full thickness) .
- . 1st and 2nd degree partial thickness burns
- donor sites, and traumatic and surgical wounds. .
Product codes
FRO
Device Description
Derma Sciences Medihoney Primary Dressings with Active Manuka Honey are sterile, single-use wound care dressings for use in moist wound management. The Derma Sciences Medihoney Primary Dressings with Active Manuka Honey are offered in several sizes including 2" x 2", ¾ x 12", 4" x 4" and 4" x 5". The dressings are comprised of honey and sodium alginate. The proposed Medihoney Primary Dressing with Active Manuka Honey contains Active Manuka Honey. As wound exudate is absorbed, the alginate forms a gel, which assists in maintaining a moist environment that aids supports the autolytic debridement for optimal wound healing, and allows intact removal. The proposed Honey Primary Wound Dresings are comprised of 80% w/w of Active Manuka Honey and 20% hydrocolloidal gelling agents.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Biocompatibility testing performed to support the formulation change for the modified dressings demonstrates that the Medihoney Primary Dressings with Active Manuka Honey are safe for their intended use. Cytotoxicity, sensitization, and irritation testing was performed successfully using the Derma Sciences Wound Dressings.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
N/A
0
K072956 page 1/3
510(k) Summary for Derma Sciences Medihoney Primary Dressings with Active Manuka Honev
1. SPONSOR
Derma Sciences 214 Carnegie Center Suite 100 Princeton, NJ 08540
NOV 0 7 2007
| Contact Person: Barry Wolfenson |
|---|
| Derma Sciences |
| 214 Carnegie Center, Suite 100 |
| Princeton, NJ 08540 |
| Telephone: 609.514.4744 x1103 |
Date Prepared: October 18, 2007
2. DEVICE NAME
| Proprietary Name: | Derma Sciences Medihoney Primary Dressings with
Active Manuka Honey |
|----------------------|------------------------------------------------------------------------|
| Common/Usual Name: | Wound Dressing |
| Classification Name: | Dressing |
3. PREDICATE DEVICES
API-MED Active Manuka Honey Wound Dressings (K053095)
4. DEVICE DESCRIPTION
Derma Sciences Medihoney Primary Dressings with Active Manuka Honey are sterile, single-use wound care dressings for use in moist wound management. The Derma Sciences Medihoney Primary Dressings with Active Manuka Honey are offered in several sizes including 2" x 2", ¾ x 12", 4" x 4" and 4" x 5". The dressings are comprised of honey and sodium alginate.
The proposed Medihoney Primary Dressing with Active Manuka Honey contains Active Manuka Honey. As wound exudate is absorbed, the alginate forms a gel,
1
K072956 page 2/3
which assists in maintaining a moist environment that aids supports the autolytic debridement for optimal wound healing, and allows intact removal.
5. INTENDED USE
The Derma Sciences Honey Primary Wound Dressing provides a moist environment conducive to wound healing and is indicated for light to moderately wounds such as:
- . diabetic foot ulcers
- . leg ulcers (venous stasis ulcers, arterial ulcers and leg ulcers of mixed etiology)
- . pressure ulcers / sores (partial and full thickness)
- 1st and 2nd degree partial thickness burns ◆
- ♥ donor sites, and traumatic and surgical wounds.
6. TECHNOLOGICAL CHARACTERISTICS AND SUBSTANTIAL EQUIVALENCE
The Derma Sciences Honey Primary Wound Dressing into the market is essentially identical to the parent API-MED Active Manuka Honey Wound Dressings subject of K0453095. The differences between the Derma Sciences Medihoney Primary Dressings with Active Manuka Honey and the predicate device are limited to a slight formulation change, the addition of an optional adhesive backing and a slight indication change.
The technological characteristics of the Derma Sciences Medihoney Primary Dressings with Active Manuka Honey and the parent API-MED Active Manuka Honey Wound Dressings are substantially equivalent in that they are all dressings suitable for use on pressure sores, leg ulcers, post-operative wounds, superficial wounds and abrasions.
The modifications made to the API-MED Active Manuka Honey Dressings to produce the Derma Sciences Medihoney Primary Dressings with Active Manuka Honey are limited to a slight change in formulation. The proposed Honey Primary Wound Dresings are comprised of 80% w/w of Active Manuka Honey and 20% hydrocolloidal gelling agents and the parent API-MED Active Manuka Honey Dressings are comprised of 95% Active Manuka Honey and 5% calcium alginate. This slight change in formulation simply provides the user with a wider variety of honey dressings and does not represent a significant change in technological characteristics of the Medihoney Primary Dressings with Active Manuka Honey. The only differences between the Derma Sciences Medihoney Primary Dressings with
2
K0729 56 page 3/3
Active Manuka Honey and the predicate devices include slightly different dressing composition which are minor and do not affect the safety and effectiveness of the device.
7. PERFORMANCE TESTING
Biocompatibility testing performed to support the formulation change for the modified dressings demonstrates that the Medihoney Primary Dressings with Active Manuka Honey are safe for their intended use. Cytotoxicity, sensitization, and irritation testing was performed successfully using the Derma Sciences Wound Dressings.
3
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of an eagle or bird-like figure, represented by a series of curved lines that suggest feathers or wings.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
NOV 0 7 2007
Derma Sciences, Inc. % Medical Device Consultants, Inc. Mary McNamara-Cullinane, RAC Senior Regulatory Consultant 49 Plain Street North Attleboro, Massachusetts 02760
Re: K072956
Trade/Device Name: Derma Sciences Medihoney Primary Dressing with Active Manuka Honey Regulatory Class: Unclassified Product Code: FRO Dated: October 18, 2007 Received: October 19 2007
Dear Ms. McNamara-Cullinane:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050,
4
Page 2 - Mary McNamara-Cullinane
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Sonall Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html .
Sincerely vo
$p^{2} f_{0}
\langle p \rangle^{0,2} \int c^{1} c^{1} d^{1} r
Mark N. Melkerson Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
Indications for Use
K072956 510(k) Number (if known):
Device Name: Derma Sciences Medihoney Primary Dressing with Active Manuka Honey
Indications for Use:
The Derma Sciences Medihoney Primary Dressing with Active Manuka Honey provides a moist environment conducive to wound healing and is indicated for light to moderately exuding wounds such as:
- . diabetic foot ulcers
- leg ulcers (venous stasis ulcers, arterial ulcers and leg ulcers of mixed . etiology)
- pressure ulcers / sores (partial and full thickness) .
- . 1st and 2nd degree partial thickness burns
- donor sites, and traumatic and surgical wounds. .
Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR
Over-the-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE)
Nol
(Division Sign-Off)
(Division Sign Of General Restorative, Division
and Neurological Devices
510(k) Number K072951